Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

PURPOSE: Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large trials. Initial data of the combined analysis of the North Central Cancer Treatm...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Perez, Edith A., Romond, Edward H., Suman, Vera J., Jeong, Jong-Hyeon, Davidson, Nancy E., Geyer, Charles E., Martino, Silvana, Mamounas, Eleftherios P., Kaufman, Peter A., Wolmark, Norman
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2011
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3164242/
https://ncbi.nlm.nih.gov/pubmed/21768458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.0868
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky